Packing batteries with more punch
Indian researchers are working on cells that can store more energy, last longer
Drug maker Glenmark Pharmaceuticals on Friday said that it has received approval from Australian regulator Therapeutic Goods Administration (TGA) to commercialise Ryaltris in Australia through its partner Seqirus.
Ryaltris is a new fixed dose combination nasal spray of an antihistamine and a steroid indicated for treatment of symptoms associated with allergic rhinitis and rhinoconjunctivitis in patients over 12 years of age in Australia.
“Glenmark... announced that Seqirus has received marketing approval for Ryaltris from the Therapeutic Goods Administration, Australia,” the company said in a filing to BSE.
This paves the way for the launch of Ryaltris in Australia through our partner, Seqirus. Australia will be the first market globally where Ryaltris will be launched, the company said.
Seqirus, part of Australia-based specialty biotechnology company CSL Ltd, entered into an exclusive licensing agreement in July last year with Glenmark’s subsidiary Glenmark Specialty S A to commercialise Ryaltris in Australia.
Under the terms of the agreement, Glenmark will be responsible for product supply and Seqirus will be responsible for regulatory filing and commercialisation of the product in Australia.
Glenmark is entitled to receive commercial milestone payments from Seqirus. Ryaltris will be manufactured at Glenmark’s Baddi manufacturing facility in Himachal Pradesh.
Australia has one of the world’s highest rates of allergic rhinitis with nearly 20 per cent of the country’s population suffering annually from this disease.
In Australia and New Zealand, Seqirus is a pharmaceutical company operating with expertise in specialty and primary care pharmaceuticals and vaccines.
The shares of Glenmark Pharmaceuticals were trading at ₹353.10 a piece on BSE in morning trade.
Indian researchers are working on cells that can store more energy, last longer
To fix a broken bone, doctors often harvest another bone from the patient’s body or from someone else. It ...
Superconductors from IIScScientists at IISc Bangalore have invented a device with a nanocrystal structure ...
Engineering and construction giant L&T has won a licence from the Council of Scientific & Industrial ...
Will a stock continue its current trend or will it reverse? We tell you how you can read chart patterns to ...
Sensex and Nifty 50 saw selling interest on Friday and slumped; selling pressure could continue
Investors with a long-term horizon can consider this offer
Most AMCs have been sending out cryptic e-mails. We tell you how to read between the lines
In these isolated times when people yearn for a slice of the familiar, amateur and professional chefs are ...
Forget the tuna. The island nation will keep you full and happy with coconut, koftas and jasmine
This year, on Facebook, I saw that someone had posted a list of EASY RESOLUTIONS. I didn’t copy them down but ...
With strokes of quirky humour, Partha Pratim Deb uses pulp, terracotta, glass and discarded cloth to create ...
Digital is becoming dominant media, but are companies and their ad agencies transforming fast enough to make a ...
Slow Network, promoted by journalist-lyricist Neelesh Misra, pushes rural products and experiences
How marketers can use the traditional exchange of festive wishes meaningfully
For Fortune, a brand celebrating its 20th anniversary, it was a rude shock to become the butt of social media ...
Three years after its inception, compliance with GST procedures remains a headache for exporters, job workers ...
Corporate social responsibility (CSR) initiatives of companies are altering the prospects for wooden toys of ...
Aequs Aerospace to create space for large-scale manufacture of toys at Koppal
And it has every reason to smile. Covid-19 has triggered a consumer shift towards branded products as ...
Please Email the Editor